Ces radiol. 2016, 70(3):129-137 | DOI: 10.55095/CesRadiol2016/020
18F-FDG-PET/MRI in children with Hodgkin's diseaseOriginal article
- Klinika zobrazovacích metod LF UK a FN, Plzeň
Aim: To evaluate the feasibility of the staging and restaging imaging of children suffering from Hodgkin's disease 18F-FDG-PET/MRI.
Method: In 12 children in the age 8 to 15 years with proven diagnosis of Hodgkin's disease, 26 procedures were performed using the integrated PET/MRI. The dosing of 2 MBq of 18F-FDG per kilogram of body weight was used. The whole-body or whole trunk imaging was used using T1 VIBE Dixon two-point, TIRM T2 STIR and DWI after application of gadolinium contrast agent. The data acquisition lasts 4 minutes in each position. All examinations were performed without need of the general anaesthesia. The imaging evaluation was driven in the intentions of the WHO Hodgkin's disease staging or during interim examinations using the Deauville score system.
Results: All examinations were evaluated as adequate from the point of view of diagnostic quality of examination, the applied radiopharmaceutical activity varied between 45 to 151 MBq. The coupled staging and interim examinations were performed in 9 children, in three children classified as score 4 or 5 according Deauville schema, the additional follow-up study was added to complete the therapy response imaging.
Conclusion: Hybrid imaging 18F-FDG-PET/MRI with low 18F-FDG-dosing reaches the optimal diagnostic quality in the assessment of the staging and also restaging of the Hodgkin's disease, when the attitude with lower 18F-FDG-dosing enables the lowering the total radiation dose burden to the ill children.
Keywords: Hodgkin's disease, 18F-fluorodeoxyglucose, PET, MRI
Grants and funding:
Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).
Accepted: September 15, 2016; Published: September 1, 2016 Show citation
References
- Tanday S. Using PET-CT to tailor treatment for Hodgkin's lymphoma. Lancet Oncol 2016; 17(8): e322. doi:10.1016/S1470-2045(16)30271-6. Epub 2016 Jun 23. PubMed PMID: 27345638.
Go to original source...
Go to PubMed...
- Platzek I. (18)F-fluorodeoxyglucose PET/MR imaging in lymphoma. PET Clin 2016; 11(4): 363-373.
Go to original source...
Go to PubMed...
- Afaq A, Fraioli F, Sidhu H, Wan S, Punwani S, Chen SH, Akin O, Linch D, Ardeshna K, Lambert J, Miles K, Groves A, Kayani I. Comparison of PET/MRI with PET/CT in the evaluation of disease status in lymphoma. Clin Nucl Med 2016 [Epub ahead of print] PubMed PMID: 27607161.
Go to original source...
Go to PubMed...
- de Oliveira Costa R, Hallack Neto A, Siqueira S, Lage LA, de Paula HM, Coutinho AM, Pereira J. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. Nucl Med Commun 2016; 37(10): 1095-1101.
Go to original source...
Go to PubMed...
- Adams HJ, Kwee TC. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients? Nucl Med Commun 2016 [Epub ahead of print] PubMed PMID: 27501435.
Go to original source...
Go to PubMed...
- Annunziata S, Cuccaro A, Calcagni ML, Hohaus S, Giordano A, Rufini V. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med 2016 [Epub ahead of print] PubMed PMID: 27246952.
Go to original source...
Go to PubMed...
- Adams HJ, Kwee TC. End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphoma. Ann Hematol 2016 [Epub ahead of print] PubMed PMID: 27590600.
Go to original source...
Go to PubMed...
- Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 2016. doi:10.1111/bjh.14292. [Epub ahead of print] PubMed PMID: 27539369.
Go to original source...
Go to PubMed...
- Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, Morgan DS, Greer JP, Smith MR, Hill BT, Reddy NM. Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. Br J Haematol 2016. doi:10.1111/bjh.14236. [Epub ahead of print] PubMed PMID: 27409578.
Go to original source...
Go to PubMed...
- Atkinson W, Catana C, Abramson JS, et al. HybridFDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol (NY) 2016; 41(7): 1338-1348.
Go to original source...
Go to PubMed...
- Grueneisen J, Sawicki LM, Schaarschmidt BM, et al. Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI. PLoS One 2016; 11(6): e0157880. doi:10.1371/journal.pone.0157880.ECollection 2016. PubMed PMID: 27327617; PubMed Central PMCID: PMC4915683.
Go to original source...
Go to PubMed...
- Ponisio MR, McConathy J, Laforest R, Khanna G. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol 2016; 46(9): 1258-1268.
Go to original source...
Go to PubMed...
- Sher AC, Seghers V, Paldino MJ, Dodge C, Krishnamurthy R, Krishnamurthy R, Rohren EM. Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: A prospective study. AJR Am J Roentgenol 2016; 206(3): 623-631.
Go to original source...
Go to PubMed...
- Albano D, Patti C, Lagalla R, Midiri M, Galia M. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 2016. doi:10.1002/jmri.25439 [Epub ahead of print] PubMed PMID: 27603267.
Go to original source...
Go to PubMed...
- Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med 2016; 374(25): 2419-2429.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.